Podcasts about royalties

Summit Royalties and Star Royalties are combining. Summit has agreed to acquire all of the issued and outstanding common shares of Star. We have new drill results out from Souther Cross Gold and Banyan Gold. Great Pacific has new exploration news out. American Pacific will begin the MT Survey over Madison. Eldorado Gold has received its Operating Authorization for the Ormaque deposits at the Lamaque Complex in Val-d'Or, Quebec. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Jim Edwards breaks down his most profitable use of writing a book. It is not book royalties, though those are nice. The biggest gains in revenue from writing a book come from a wide variety of uses of the book as leverage to sell higher-priced items in your business. Things like coaching programs, courses, and membership programs are bigger ticket items you can and should use your book to leverage. Check out more of Jim Edwards coaching and software programs for content marketing and sales copywriting at https://www.copyandcontent.ai. Save time and make money using the programs and his coaching. 

Interview with David Christie, President and COO, Globex MiningOur previous interview: https://www.cruxinvestor.com/posts/globex-mining-gmx-unique-project-generator-and-royalty-company-3060Recording date: 5th of March 2026Globex Mining Enterprises is executing a distinctive strategy in the resource sector, operating as a royalty generator that creates its own revenue streams through counter-cyclical property acquisitions. With 107 royalties across 270 mineral assets, the company is transitioning from opportunistic project generator to established royalty company as multiple properties advance toward production.President and COO David Christie articulates the company's approach: acquiring undervalued properties during commodity downturns, developing them through exploration, and selling to operators while retaining royalty interests. The antimony properties in New Brunswick exemplify this strategy—acquired when the metal received minimal investor attention, these assets now benefit from heightened strategic interest as they advance toward production.Globex's financial position distinguishes it from typical junior resource companies. The firm holds over $40 million in cash and securities, split evenly between liquid cash and equity positions in senior producers including Eldorado Gold, Pan American Silver, and Alamos Gold. This balance sheet strength, combined with approximately $5 million in annual revenue from option payments and advance royalties, eliminates dilution pressure and provides strategic flexibility.The company maintains a commodity-agnostic portfolio spanning precious metals (50%), base metals (25%), and specialty commodities (25%) including manganese, fluorspar, and rare earths. Over 300,000 meters of drilling are planned across Globex properties this year, primarily funded by option partners, including 140,000 meters at the O'Brien project and 250,000 meters at Cadillac.Multiple production catalysts are emerging within a 1-5 year timeframe. Bell Mountain heap leach gold operation targets late 2026 production, while Mont Sorcier iron ore project advances toward feasibility study completion in summer 2026. New Brunswick antimony-gold and manganese projects are progressing rapidly toward development.With only 56 million shares outstanding and no rollbacks since its 1987 founding, Globex has demonstrated disciplined capital management. As royalty cash flows materialize, the company maintains optionality for acquisitions, asset spin-outs, or potential acquisition by larger royalty consolidators seeking growth and commodity diversification.Learn more: https://www.cruxinvestor.com/companies/globex-miningSign up for Crux Investor: https://cruxinvestor.com

Dr. Pedro Barata and Dr. Kathryn Schmitz discuss evidence-based exercise oncology programs, how to incorporate exercise into cancer care and connect the right patient to the right program, and ultimately build a culture of exercise in oncology. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist and a clinical trialist at the University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also happy to serve as a deputy editor for the ASCO Educational Book. Today, we'll be talking about exercise. We have plenty of evidence that exercise benefits symptoms, improves the quality of life of patients, and actually has been shown to reduce risk of recurrence of cancer but also improve survival. And I think that's increasingly clear as data emerges. Today, I'm delighted to be speaking to Dr. Kathryn Schmitz. She's a leading expert on integrating exercise into cancer care. Dr. Schmitz serves as the deputy director of the University of Pittsburgh Hillman Cancer Center and also a professor of hematology-oncology at University of Pittsburgh Medical School. She's the senior author of a fantastic article in the ASCO Educational Book that's titled "Implementation Science as the Secret Sauce for Integrating Exercise Screening and Triage Pathways in Oncology." She also led a really compelling piece that just got published in JCO titled "If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not" So I'm thrilled to have Dr. Schmitz joining us today and helping us explore evidence-based exercise oncology programs, how to incorporate exercise into cancer care, and also how to connect the right patient to the right program.  So with that, welcome, Dr. Schmitz. Thank you so much for taking the time to chat with us. Dr. Kathryn Schmitz: Thank you for the opportunity. Dr. Pedro Barata: One of the highlights of ASCO last year and practice changing, in my opinion, data out of The New England [Journal of Medicine] is called the CHALLENGE trial. It did provide high level evidence that a structured, supervised exercise program could improve both disease-free survival and overall survival. This is a study in the GI world, but I think it got a lot of attraction and attention beyond the GI world, across solid tumors, really. Could you give us a little brief recap of that trial and what have you seen as being the impact in practices around oncology? Dr. Kathryn Schmitz: So, CHALLENGE was very exciting. Prior to CHALLENGE, there were any number of observational studies that indicated that there was a relationship between being more physically active and reduced recurrence and improved overall survival for colon cancer in particular. You know, notably, in 2006, Jeff Meyerhardt published two papers in the same journal, of the same issue of JCO, showing very, very similar data from two very large studies. And those were studies number five and six in this area. You know, there's a lot of evidence observationally, but we don't generally change clinical practice on the basis of observational data. So, we were all waiting very impatiently for the results of the CHALLENGE trial. And it was very exciting to be in the front row when the results were reported out and to be part of the group with a standing ovation for the authors when it was presented. To summarize, 889 colon cancer patients, stage II and III, were randomized into either a structured exercise program or a health education control comparison group and followed for an average of 7.9 years. And the structured exercise group had a 27% reduced risk of recurrence and a 38% improvement in overall survival. One of the things that's really notable about this is that what we typically expect is that when we go from the observational literature to the clinical trial literature, that we expect effects to go down. We expect to see a larger effect in the observational than in the RCT land, and that did not happen here. We actually see an effect that matches what we've seen in observational literature, which is really, really exciting.  And, you know, one of the reasons why this has been so exciting across not just GI but other cancers is the notable finding of a reduced risk of second primaries. So, they only observed two breast cancer second primaries in the treatment group and 12 in the comparison group. And overall, they reduced the second primaries occurrence, hazard ratio was 0.5, a 50% reduction of second primaries, which is just remarkable. It really got everybody very, very excited. And now the big question, of course, is, all right, how do I do this? How do I make this happen?  The thing to note is that what they did in CHALLENGE is probably not doable in your clinic tomorrow. It's a heavy intervention. The number of touchpoints from staff is extensive, and the amount of time needed from staff for the coaching and supervised exercise is extensive as well. The criteria for getting people into the program required that people go through a series of blood tests and imaging tests that would just simply not be possible for the average community oncologist. So I'm guessing that you're going to ask me some questions about how we do this. Dr. Pedro Barata: Right. That's a fantastic segue. That's exactly right. Walk us through maybe starting by, what does that mean? Dr. Kathryn Schmitz: The first thing to say is I have to go back to the observational literature. And the observational literature shows really compellingly that we have a strong reduction of breast cancer recurrence and mortality from being more physically active, prostate cancer recurrence and mortality, and colon cancer recurrence and mortality. I find it very difficult to believe in this day and age, in our current environment, if you will, that we are ever going to have the equivalent of CHALLENGE for prostate or for breast cancer. There is an ongoing study in prostate that's led by some Australian researchers, but I just don't think that it's likely that we're going to mount something similar for another tumor site. We have tremendous correlative data that indicates that there are a number of biomarkers and biological pathways through which breast, colon, and prostate cancer would be reduced in recurrence if people were more physically active. And so, there is really, from my thinking, very little to state that it would be just a colon cancer effect. And so this is something we probably can enact in more than just the colon cancer community, overall, which is great news, and it makes it easier for us to be able to enact this type of programming. Dr. Pedro Barata: One of the things that comes up perhaps often is, if I were the leader of the cancer center and were to incentivize the different care teams to implement an exercise program at each level: GI team, GU, breast, thoracic, etc. How do we do that? Dr. Kathryn Schmitz: So, I want to give you an analogy. You're a medical oncologist, and you prescribe your patients chemotherapy. Now, just imagine, if you will, what would happen and how likely it would be for your patients to get chemotherapy if there was no chemoinfusion suite. If the chemoinfusion suite disappeared tomorrow and you were to tell your patients, "Go get some chemotherapy," what proportion of those patients do you think would go find all of the equipment necessary and all of the drugs necessary and understand how to dose the chemotherapy for themselves and get that all done? Very few people would do it. So with exercise, why would we be surprised then that our patients don't actually do a whole lot if we just simply tell them to go get some exercise? Exercise is a medicine. It is effective like a medicine. We've shown this through the CHALLENGE trial and many other correlative studies and an ocean of observational data as well. So the question is, how do we build the infrastructure that is necessary in order for your patients to do this? So the very first thing that has to happen is that somebody has to tell the patient to exercise. We currently do not have a culture of exercise in oncology. We do in heart disease. If you ask the average person on the street, "Is exercise good for your heart?" Anybody with an eighth-grade education is going to say, "Yes, of course," because the American Heart Association has done an amazing job telling everybody that exercise is good for your heart. But what has ASCO done, frankly? Can I be that bold? What has ASCO done to tell patients that they should be exercising during and after their cancer treatment? I'm not sure that I know more than a guideline. There is a guideline, and that's great. And the guideline is very helpful, but I'm not sure that patients know that there's a guideline. In fact, I can tell you that patients don't know that there is a guideline. So, you know, making sure that there's a paradigm shift in the country that says exercise is good for patients during and after their cancer treatment is the first step. The second step is getting a medical professional to say something to the patient about the exercise. And I'm very careful with the two words that I just chose: medical professional. I do understand medical oncologists are very busy. I understand that there's a whole lot to say in that 15 minutes when you're with the patient. And so maybe it isn't the medical oncologist. Ideally, it would be, but I get it that there's limited time. So it could be a nurse practitioner, it could be a nurse, there could be a social worker, it could be somebody else on the team that says, "Hey, you know, we want you to do an exercise program. We want to connect you to an exercise program." And then there's what is the program itself? You know, I'm very interested in this happening across the entire country. And so I've been working with the leadership of the Commission on Cancer on the question of, well, how would you do this in community oncology? You know, it's not enough to do it in academic medicine, but how do you do this in community oncology? And you can't expect that every community hospital is going to build a gym for their cancer patients. That is just not reasonable to do. So, we start to try to figure out some phone counseling. Could we give people Fitbits and follow them? Could we use technology to help us? Are there telehealth opportunities for us to do? Are there apps that have been built? In fact, there is a [free] app called Cancer Exercise that's on, you know, all of the platforms and available to patients. So there are programs. I've developed a directory of over 2,000 programs that exist across the country for exercise oncology that patients can find, medical oncologists can find.  So there are a lot of people trying to figure out how best to get the information to medical oncologists and other medical professionals so that they can have an 'easy button' to be able to connect their patients to existing programming so that you don't feel like you have to build a whole new program. Dr. Pedro Barata: If I don't have the resources around me, what would be your advice for the care team or for the providers that might not have that available at their site? Where do they start? Who do they reach out to? Who should they be looking at to get more information on how to set it up? Dr. Kathryn Schmitz: I lead an international consortium called Moving Through Cancer. You can find us at movingthroughcancer.org. That's where you'll find the map of all of the programs across the country and the directory. We actually have a triage tool that sits at the front of the directory that allows people to discern what type of exercise they're safe to do. We do recognize that, you know, the 80-year-old that fell last week doesn't need the same program as the 35-year-old that was playing pickleball the day before diagnosis. So, you know, there are different kinds of programs for people at different levels of acuity. We're happy to be helpful to folks to help them set up programs.  But the number one thing is to really be very aware of the power of saying something about doing exercise, just simply the power of saying, "I want you to be moving." Because frankly, I don't think anybody listening to this would disagree, no one benefits from sitting on the couch all day, no one. No one, no one. It doesn't matter how acute their medical issues are. We get people out of bed. We try to move people even when they're in the hospital. So I think saying something is huge. And then, if you can, applying a triage tool, if you can get something embedded within your clinical flow so that you can understand who it is that needs to go to physical therapy as opposed to who's ready for an exercise program. Those are the two things. So triage and referral is kind of step one. And if you can get that done, the rest will fall into place. Dr. Pedro Barata: This is really powerful message, where one, awareness of the care teams. Number two, bring it up to the patient. And then working on the referral, triage and referral process. That's fantastic. Another aspect that comes up quite a bit is like, "Look, this is great, but we have a system that relies on payers to make things happen, or at least to get them approved." And that can be very different or heterogeneous. The coverage can be different. Sometimes already going through a system programs for interventions, therapeutic interventions, let alone probably the insurance is not going to cover that. Is that true? Is it not true? How do you walk through the different insurance supports, perhaps, depending on where you're practicing? Dr. Kathryn Schmitz: You've just hit on the hot button. I've been working on this issue for about nine years now, trying to figure out using efforts to talk to CMS and see if we can get third party payer coverage going. We were making good progress there, and there was a change of administration and a new focus on "Make America Healthy Again," the MAHA movement. And, you know, CMS is really no longer interested in one-off national coverage determination. They instead, they want to know, "How do we make exercise happen for every American over 65?" And my question is, "Well, wait a minute, cancer patients are not just older patients. There's a lot going on there. They need something special." So I've been working on that. It's been working with accrediting bodies for policy with a little p. Very proud of the work that I've done in collaboration with the National Accreditation Program for Breast Centers, trying to get standards to get exercise referrals for breast patients. And I'm currently holding my breath to see whether the CoC is going to try to make some forward motion in this area as well, crossing all period appendages, waiting for news there. So it's not paid for unless it's done by a physical therapist. And, you know, there's published evidence and I have plenty of evidence from UPMC as well, that people don't really want to go to the physical therapist for this. I'm not saying physical therapists aren't great. Physical therapists are great, and there are people who really need to go to physical therapy, and we try hard to get those patients connected. But for the patients that are ready for something more than physical therapy, we really have an uphill battle to try to figure out what insurers are willing to pay for and what the return on investment is.  One of the challenges with the return on investment is that the timeline, time course for return on investment for American insurers is about one year. And I'll remind you that the time course for return on investment for CHALLENGE was 7.9 years. So we have a mismatch there. So we're trying to figure out if we can produce the evidence to show that there is an improvement in unplanned health care utilization. We have documented that for breast cancer. We're working on it for other cancers. If we can document that it is worthwhile to the insurer to pay for these programs, then I believe that they will pay for them. You know, my conversations are very positive with UPMC, which is a very large insurer and a large health plan. We're slowly working our way towards the middle, where there's a program that they can pay for and a program that is efficacious. That's the puzzle we're trying to solve for right now. Dr. Pedro Barata: This has been wonderful and super helpful. Before we wrap it up, is there anything else you would like to share with our listeners? Dr. Kathryn Schmitz: I want to make sure that your audience is aware that there are a variety of ways that exercise oncology is practiced. The program that most oncologists will be familiar with is LIVESTRONG, which is a program at the YMCA. It's a free program. At one point, there were over 800 locations across the U.S. They have contracted since COVID, probably because of COVID. So they still do exist but imagine, if you will, telling your patients that chemo is only available Tuesdays and Thursdays at 7:00 p.m. It would be difficult for patients to get there and get the chemotherapy. The same thing is true for the LIVESTRONG program. It's a fantastic, fantastic program for people who are able to get there, but that's one option. Another option for patients is there are a variety of online opportunities. I'll call out 2Unstoppable for women's cancers. It's literally the number 2Unstoppable.org. It's a free program available to women with cancer to have live, small group training programs. And they're based in Virginia, but they have programs all over the country. And then finally, I just want to overemphasize the app, the Cancer Exercise app. It's literally called Cancer Exercise in the app store. And that is a super duper easy button, very comprehensive, developed by a nurse scientist, Anna Schwartz. And then there are a variety of books. I wrote a book called Moving Through Cancer. There's a new book out [MyExerciseMedicine for Cancer] by Dr. Rob Newton as well, who's an Australian author. And there are certifications for exercise professionals that folks can look into as well through the American College of Sports Medicine. Dr. Pedro Barata: Dr. Schmitz, this is fantastic. Thank you for sharing those great insights with us. Super, super helpful. Thank you for taking the time. Dr. Kathryn Schmitz: Thank you so much. Dr. Pedro Barata: Thank you to our listeners for your time today. Remember, you'll find links to Dr. Schmitz's fantastic Educational Book as well as the JCO articles in the transcript of this episode. I'll invite all of you to go and read. And we'll also include a link to Dr. Schmitz's book titled Moving Through Cancer: An Exercise and Strength Program for the Fight of Your Life, which empowers patients and caregivers in simple five steps.  So with that, please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you very much for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:           Dr. Pedro Barata    @PBarataMD     Dr. Kathryn Schmitz @fitaftercancer Follow ASCO on social media:           @ASCO on X (formerly Twitter)           ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Pedro Barata:    Stock and Other Ownership Interests: Luminate Medical    Honoraria: UroToday    Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon    Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas    Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck     Dr. Kathryn Schmitz: Patents, Royalties, Other Intellectual Property: Fees from the educational program developed by Dr. Schmitz that is now offered through Klose Training and Consulting.

Texas Pacific Land wirkt auf den ersten Blick wie eine weitere Öl Aktie. Nur bohrt TPL nicht, fördert nicht, betreibt keine Raffinerien. Das Unternehmen verdient an etwas Grundsätzlicherem, an Land, Rechten und einer Position im Herzen des Permian Basin, die seit Jahren wie ein stiller Cashflow Magnet wirkt.Genau dieser Hebel ohne klassisches Ölgeschäft ist der Kern der Analyse. Warum konnte eine Landgesellschaft über ein Jahrzehnt eine Rendite liefern, die sonst eher bei Tech-Unternehmen wie Nvidia erwartet wird, und was davon ist wirklich wiederholbar. Im Video geht es darum, wie Royalties, Flächennutzung, Infrastruktur und das oft übersehene Wasser Thema zusammenspielen, wo der Burggraben tatsächlich liegt und welche Abhängigkeiten Anleger trotzdem nicht unterschätzen sollten.Ein zweiter Schwerpunkt ist die Bewertung. Wenn eine Aktie so weit gelaufen ist, stellt sich nicht mehr die Frage, ob das Geschäftsmodell stark ist, sondern was davon bereits im Kurs steckt. Der Blick richtet sich auf Kennzahlen, Kapitalallokation und die aktuelle Marktphase, inklusive der Frage, wie mit einer Aktie umzugehen ist, die nahe wichtiger Zonen handelt und historisch eher in Treppenstufen steigt.

Interview with Brendan Yurik, CEO of Electric Royalties Ltd.Our previous interview: https://www.cruxinvestor.com/posts/mining-royalty-sector-explodes-with-massive-consolidation-fresh-capital-7469Recording date: 3rd March 2026Electric Royalties Ltd. is a clean energy metals royalty company with a portfolio of 43 royalties across copper, graphite, lithium, tin, manganese, zinc, and nickel. At a current market capitalisation of under C$20 million, the company is valued at a significant discount to the royalty sector — both relative to early-stage peers with one or two royalties trading above $200 million, and to mid-tier royalty platforms trading well above $1 billion. For investors with a multi-year time horizon, this disconnect between current pricing and the underlying portfolio's development trajectory is the central element of the investment case.The company operates with a deliberately lean cost structure with annual G&A is approximately $1 million. One producing royalty at the Punitaqui copper-gold mine in Chile, backed by the Yorktown Group's $3.2 billion private equity platform, is expected to generate over $500,000 in revenue this year, with a near-term target of $1 million. This means the company is approaching cash flow self-sufficiency from a single asset, leaving the remaining 42 royalties to contribute upside without the overhead burden that would typically accompany a portfolio of this scale.The next two to five years represent the key inflection window. Four royalties in particular stand out as near-term production candidates. Mont Sorcier, an iron-vanadium project in Quebec partnered with Glencore and backed by $500 million in UK Export and Import Bank financing, has a feasibility study due in Q2 2026 and a projected 40-plus-year mine life. Management estimates it could add US $1 million to $1.5 million annually in royalties alone. Bissett Creek, a graphite project operated by Northern Graphite with Canadian government funding, is targeting production at four times its original scale, with 70 years of resources at the prior production rate. The Zonia copper project in Arizona, now the sole focus of Edge Copper, has doubled its resource to one billion pounds of copper and is moving toward a feasibility study. Seymour Lake, a lithium project, has secured a $100 million Canadian government letter of intent and is targeting production within two to three years. Each of these royalties entering production would individually add eight times or more of current annual revenue.A structural advantage underpins the company's acquisition strategy. Private equity funds dedicated to clean energy metals typically require deal sizes above $15 million, leaving the majority of royalty opportunities accessible only to smaller, more flexible platforms like Electric Royalties. This has allowed the company to build its portfolio at entry costs that are now difficult to replicate, with some royalties acquired for $150,000 to $200,000 on projects that have since had $50 million to $100 million invested by operators.Strategic M&A is under active consideration as a complementary growth path. Combining portfolios with another royalty company would diversify revenues and spread fixed costs across a broader asset base. With over 50% of shares held by management and their families, the company is protected from hostile approaches while remaining a willing participant in value-accretive consolidation. For investors, the combination of a deeply discounted entry valuation, a near-term production catalyst funnel, government capital backing key assets, and M&A optionality represents an unusual convergence of risk-adjusted return potential in the critical minerals sector.View Electric Royalties' company profile: https://www.cruxinvestor.com/companies/electric-royaltiesSign up for Crux Investor: https://cruxinvestor.com

Interview with Drew Clark, CEO, Summit RoyaltiesRecording date: 3rd of March 2026Summit Royalties has emerged as a new entrant in the precious metals royalty sector, building a 47-asset portfolio in just four months while achieving cash flow positivity from inception. The company executed three major transactions between May and September 2025, acquiring portfolios from IAMGold for $17.5 million, completing a reverse takeover with Eagle Royalties, and purchasing the Madsen royalty from Sprott. In total, Summit raised approximately $23 million USD while maintaining a disciplined capital structure that has never issued warrants, a rarity among junior resource companies.The company currently generates revenue from three producing assets. The Madsen mine in Ontario holds a 1% net smelter return royalty yielding approximately 500 ounces of gold annually from a high-grade operation guiding for 50,000 ounces in 2025. Summit also holds a 50% silver stream on Orezone at no ongoing cost, receiving a minimum of 37,500 ounces annually as the mine expands from 120,000 to 250,000 ounces of gold production. The third asset, Zancudo, is installing a mill in Q3 2026 to increase production capacity. Notably, all three producing assets are currently expanding operations and reserves.Summit operates with only two full-time employees who have collectively completed $2 billion in royalty transactions over the past decade. CEO Drew Clark previously executed 27 of 32 deals at Metalla Royalty, while VP Connor Pugliese comes from Triple Flag where he executed half a billion dollars in streaming transactions. Management and directors own 15% of the company, aligning incentives with shareholders.Trading at approximately $85 million USD market capitalisation and 0.75-0.8x net asset value, Summit represents a significant discount to peers trading above 1.2x NAV. The stock has appreciated from $0.90 to $1.60 per share in less than four months. Management targets scaling to $10 million in annual revenue and $200-300 million market capitalisation through accretive portfolio acquisitions, positioning Summit to unlock institutional investor access and valuation re-rating as the company crosses critical size thresholds in the consolidating precious metals royalty sector.Learn more: https://www.cruxinvestor.com/companies/summit-royaltiesSign up for Crux Investor: https://cruxinvestor.com

Summit Royalties CEO Drew Clark joined Angela Harmantas at the Prospectors & Developers Association of Canada or PDAC conference in Toronto to share news about the company's rapid transformation following its recent listings on the OTC Markets and the TSX Venture Exchange. Summit Royalties Ltd has grown significantly over the past year, moving from having no assets and minimal cash to building a diversified portfolio of 47 royalties and becoming a cash-flowing business listed on two exchanges. Clark described the journey as “a hell of a journey,” highlighting the company's three major acquisitions that reshaped the business. Clark explained that Summit's core investment strategy is focused on increasing per-share value through disciplined acquisitions. “To grow the per share value of the business every day is what we strive to do,” he said, noting that this approach applies whether the company is acquiring operating or development-stage assets. The portfolio remains primarily focused on gold and silver royalties, providing exposure to strong metal prices while maintaining diversification. No single asset represents more than 20% of net asset value, reducing risk while allowing upside across the portfolio. Clark also pointed to approximately $300 million in capital being deployed by counterparties across Summit's portfolio, supporting production growth, mill installations, and expanded drilling. With research coverage expected from investment banks and increased marketing toward US investors, the company is positioning itself for broader visibility. #proactiveinvestors #summitroyalties #tsvx #sum #otcqb #summf #pdac2026 #DrewClark #RoyaltyCompany #GoldRoyalties #SilverRoyalties #MiningStocks #TSXV #OTCMarkets #PreciousMetals #ResourceInvesting #CashFlow #MiningInvestment

On today's episode, Dr. Mark Costes sits down with Nathan Raborn, a senior wealth manager at Eckard Enterprises who brings a unique perspective on alternative investments after spending over a decade in the oil and gas sector at ExxonMobil. Nathan shares how he transitioned from managing short-term and mid-term rental properties to focusing almost entirely on mineral rights and working interest investments. He explains why real estate wasn't delivering the cash flow he expected, and how oil and gas opened up new possibilities for passive income, portfolio diversification, and significant tax advantages.  You'll hear a clear breakdown of mineral rights vs. working interests, real-world returns, tax strategies (including Roth conversions and 1031 exchanges), and how Eckard differentiates itself in a space often filled with bad actors. This is a must-listen for high-income earners looking to keep more of what they earn and grow wealth through alternative channels. Be sure to check out the full episode from the Dentalpreneur Podcast! EPISODE RESOURCES https://eckardenterprises.com https://www.truedentalsuccess.com Dental Success Network Subscribe to The Dentalpreneur Podcast

Lundin Gold has done a $670M silver stream-for-equity transaction with LunR Royalties. Bonterra Resources announced is updated mineral resource estimates for the Barry and Gladiator deposits. Koryx Copper announced assay results from 13 drill holes. Corporate updates from Gold Hart Copper, Revival Gold and Integra Resources. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to discuss the company's financial results for the first quarter ended December 31, 2025, highlighting revenue growth, rising royalties, and improved margins compared to the same period last year. The company reported higher Q1 revenue year-over-year, driven primarily by large-scale machine sales and increased royalty income. During the quarter, EnWave commissioned one large-scale machine and completed the fabrication of two additional large-scale machines under contract, contributing to the revenue uplift. Charleton noted that royalties—excluding exclusivity payments—increased by 18% compared to the same quarter in the prior year. Total reported royalty revenue for Q1 2026 rose 12% year-over-year. The growth was attributed to a combination of factors, including an expanding base of royalty partners, increased product sales, higher partner production volumes, and exclusivity payments recognized during the quarter. Profitability metrics also improved meaningfully. Gross margin for Q1 2026 reached 37%, up from 29% in the three months ended Q1 2025. Management attributed the margin expansion to a stronger contribution from higher-margin royalty revenue as well as the production mix of large-scale machines at various stages of fabrication and commissioning. Operationally, the quarter included several strategic milestones, with EnWave signing new contracts across multiple jurisdictions, including North Queensland, Australia, New Zealand, and the United States. The company said these agreements further expand its global footprint and reinforce demand for its proprietary dehydration technology platform. #proactiveinvestors #enwavecorporation #tsxv #enw #EarningsReport #RevenueGrowth #RoyaltyRevenue #MarginExpansion #DehydrationTechnology #FoodTech #IndustrialInnovation #MachineSales #GlobalExpansion #AustraliaBusiness #NewZealandBusiness #USBusiness #TechCommercialization #ManufacturingGrowth #IPLicensing #OperationalMilestones

What does it really mean to invest in mineral rights?In this episode of the Alternative Investing Advantage Podcast, Alex Perny sits down with Troy Eckard of Eckard Enterprises to break down how mineral rights investing works and why it has become an attractive alternative asset for long-term income and portfolio diversification.Troy explains how mineral ownership differs from traditional real estate, how lease agreements generate royalty income, and why investors can benefit from oil and gas production without taking on drilling costs or environmental liability. The conversation also covers how mineral rights are valued, the impact of commodity prices, tax advantages available to investors, and how technology continues to expand recoverable reserves in major U.S. energy basins.Whether you're exploring alternative real estate strategies, energy investing, or passive income opportunities, this episode provides a practical introduction to investing in mineral rights and understanding how royalty-based income works.00:00 Intro & Episode Overview01:13 Troy Eckard Background03:08 What Mineral Rights Actually Are05:40 Why Troy Chose Oil & Gas Investing08:54 How Mineral Lease Income Works11:49 Tax Treatment of Mineral Income13:14 How Mineral Rights Are Valued20:04 Technology & Oil Price Economics24:00 Demand for Fossil Fuels Explained31:55 Mineral Rights vs Traditional Real Estate37:53 Long-Term Income Potential41:46 Natural Gas, LNG & Market Factors47:13 Geopolitics & Energy Prices51:38 Due Diligence for Investors53:32 How to Contact Troy Eckard54:43 Closing ThoughtsSubscribe to our YouTube channel and join our growing community for new videos every week.If you are interested in being a podcast guest speaker or have questions, contact us at ⁠⁠⁠⁠⁠⁠⁠⁠Podcast@AdvantaIRA.com⁠⁠⁠⁠⁠⁠⁠⁠.Learn more about our guest, Troy Eckard:https://eckardenterprises.com/about-eckard-enterprises/Learn more about Advanta IRA: https://www.AdvantaIRA.com/ https://podcasters.spotify.com/pod/show/advanta-irahttps://www.linkedin.com/company/Advanta-IRA/https://twitter.com/AdvantaIRA https://www.facebook.com/AdvantaIRA/ https://www.instagram.com/AdvantaIRA/#MineralRights #OilAndGasInvesting #RoyaltyIncome #PassiveIncome #AlternativeInvesting #EnergyInvesting #RealEstateInvesting #SelfDirectedIRA #PortfolioDiversification #CashFlowInvestingAdvanta IRA does not offer investment, tax, or legal advice nor do we endorse any products, investments, or companies that offer such advice and/or investments. This includes any investments promoted or discussed during the podcast as neither Advanta IRA nor its employees, have reviewed or vetted any investments, persons, or companies that may discuss their services during this podcast.  All parties are strongly encouraged to perform their own due diligence and consult with the appropriate professional(s) before entering into any type of investment.

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) CEO Paul McGlone talked with Proactive's Stephen Gunnion about second-quarter KPIs, highlighting growth in automotive royalties, Guardian hardware sales, and increasing annual recurring revenue as regulatory tailwinds build toward the July 2026 General Safety Regulation (GSR) deadline. McGlone said he was “really pleased to see a positive growth number in this quarter,” noting confidence that regulatory drivers would translate into rising volumes. While the timing of step-change growth remains uncertain, he emphasised that OEM compliance preparations for GSR are well underway, with all required integration work already completed for the 2026 deadline. The discussion addressed RFQ delays across the automotive market, which McGlone attributed to broader industry uncertainty. However, he clarified that these delays have no impact on GSR-related production volumes, as current RFQs would not affect revenue until 2028 at the earliest. A key focus was Seeing Machines' guaranteed volume arrangements, which underpin cash flow. McGlone explained that these agreements set a revenue floor, ensuring minimum payments regardless of production variability. In Q2, actual volumes exceeded minimum guarantees for the first time under the arrangement, strengthening confidence for Q3 and Q4. He added that incumbency advantages in Europe position the company strongly ahead of GSR enforcement, and reaffirmed expectations of cash flow breakeven in Q3 and profitability in the second half. For more interviews like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss future updates. #SeeingMachines #PaulMcGlone #AutomotiveTech #GSR2026 #DriverMonitoring #AutomotiveRoyalties #VehicleSafety #OEM #GuardianSystem #RecurringRevenue #AutoIndustry #InvestorUpdate #RoadSafetyTech

If you've ever wondered how to get paid for the true value you bring to a company through campaigns they run year after year – and long after you write the initial copy → you need to hear from one of the GOATs, Kim Krause Schwalm. In this case-study-style episode, Kim lets us in on what went on behind the scenes as she grew from an in-house employee to a highly successful and sought-after copywriter in the industry, sitting in rooms with people like Eugene Schwartz and other greats. Not only that, but Kim walks us through her personal methodology for testing ‘controls' and trying to beat your own copy - ultimately increasing the value you bring to the table with every client who hires you.   If you're a copywriter curious about how to negotiate royalties into your contracts and get paid on a whole new level, this episode of the Freedom Found Copywriter Podcast is an absolute must-listen.   Tune in To Learn: What a ‘Control' is in Copywriting and why you should be testing yours asap How to negotiate royalties with big & small clients The best way for Copywriters to get hired, even in the face of AI How Kim Krause Schwalm mastered her craft, client relations, and career as a copywriter   **********   Like this show? Write a 5-star review — even just one sentence helps us bring you more content each week.    Resources & Follow: ***Get Kim's limited-time deal → Save 60% on Kim's Top 4 Trainings for Copywriters UNTIL MARCH 31, 2026 MIDNIGHT PT >>> Use code SAVE60 here: https://kimschwalm.com/training/  This includes 60% off: Million-Dollar Controls & The Get Dangerously Good Copywriting System and more! → Learn more about Kim's Trainings here: https://kimschwalm.com/training/    Connect with Krystle: → The KC Website: https://krystlechurch.com/  → Juno Membership for Copywriters: https://krystlechurch.com/Juno  → Get *Probably* The Best Copywriting Newsletter You'll Ever Read: https://krystlechurch.com/copy-classroom  → Follow on IG: https://www.instagram.com/krystle.church 

Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) CEO Marc Bishop Lafleche talked with Proactive's Stephen Gunnion about a pivotal period for the company as it enters a new phase of growth driven by base metals and critical minerals. Lafleche explained that 2025 marked an inflection point for Ecora Royalties, with base metals and critical minerals representing the majority of portfolio revenue for the first time in at least 25 years. He described the year as a “landmark year,” highlighting that the performance was underpinned by a 150% increase in base metals revenue compared with 2024. The CEO outlined how this momentum was driven by a combination of higher production volumes and favourable commodity prices. Strong volume growth was recorded at the Voisey's Bay cobalt stream, as the mine continued to ramp up, with further increases expected. Additional growth came from the Mimbula copper stream, acquired in March last year, which is now operating at an annualised rate of around 20,000 tonnes of copper and is expected to expand further through 2026. Mantos Blancos also delivered a standout performance following debottlenecking initiatives completed in 2024. Discussing the balance sheet, Bishop Lafleche noted that despite acquiring a US$50 million producing copper stream, net debt had reduced from nearly US$130 million to approximately US$85 million by the end of Q4, supported by strong cash flow generation. He said, “that really strong deleveraging is in part a function of the strong cash flow generation of this portfolio.” Looking ahead, the CEO highlighted layered growth opportunities, including production increases at existing assets, brownfield expansions, near-term development projects such as Santo Domingo and West Musgrave, and longer-term catalysts across the portfolio. With supportive commodity prices for copper, cobalt and uranium, he said the outlook for Ecora Royalties remains very positive. For more interviews and insights like this, visit **Proactive's YouTube channel**, and don't forget to **like the video, subscribe to the channel, and enable notifications** so you never miss an update. #EcoraRoyalties #MarcBishopLafleche #MiningRoyalties #BaseMetals #Copper #Cobalt #CriticalMinerals #MiningStocks #ResourceInvesting #Commodities #MiningCEO #ProactiveInvestors

In this episode of Mission Matters, Adam Torres interviews Todd Rustman, Partner at Clarity Capital Partners and author of “Memory Royalties: The Missing Link in Your Wealth Management.” Todd shares how his Midwest work ethic shaped his career in finance and explains why modern wealth management should account for “memory royalties”—experiences and moments that compound in value over time. The conversation also explores evolving retirement realities, purposeful living, and how constant learning helps families build both financial confidence and a meaningful legacy. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Mission Matters, ⁠Adam Torres⁠ interviews ⁠Todd Rustman⁠, Partner at Clarity Capital Partners and author of “Memory Royalties: The Missing Link in Your Wealth Management.” Todd shares how his Midwest work ethic shaped his career in finance and explains why modern wealth management should account for “memory royalties”—experiences and moments that compound in value over time. The conversation also explores evolving retirement realities, purposeful living, and how constant learning helps families build both financial confidence and a meaningful legacy. Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠https://missionmatters.lpages.co/podcastguest/⁠ Visit our website: ⁠https://missionmatters.com/⁠ More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ep. 176: In 2026, labels, artists, musicians and creators are all working differently: generating millions of micro-royalties every month across global campaigns that involve multiple of partners across dozens of countries. Getting your music out there is easier than ever, but processing that increased volume of payouts becomes more complex – and we all have an expectation to get paid fast, and see what's going on and what we're owed at any given time. So to find out what's happening at the point where all those payment pipes meet, in this latest episode of Music Ally Focus, we partnered with a fintech company that processes tens of billions of payments each year – Tipalti, which works closely with labels like Ninja Tune to pay their artists what they're owed. We chatted to Tipalti's Travis Hughson about what labels need in 2026, what artists want when it comes to payments, and how to maintain trust and transparency to keep all parties happy.Some more Tipalti resources for the music business:Automated Royalty Payouts to Nurture ArtistsNinja Tune Enhances Artist Satisfaction and Cuts Payouts Processing Time by 50% With Tipalti Mass PaymentsFast, Secure Global Payments AnywhereRoyalty Rate Explained: How to Determine Your Royalties========This is a Music Ally Co-Labs podcast: ⁠⁠⁠⁠musically.com/music-ally-co-labs. Co-Labs content is created by publishing partners in liaison with the Music Ally Editorial Team. We work closely with partners to ensure that it adheres to Music Ally's high expectations of quality, thoughtfulness, and usefulness.

Roxanne Shanté Speaks Out: Roxanne Roxanne 2, Tears, Rap Battles & Lost Royalties + More See omnystudio.com/listener for privacy information.

It's our very first show of the year AND one of our biggestshows of the year. It's our annual Royal Rumble preview show! ALL OUR LINKS: https://linktr.ee/KOTR_PodcastMERCHANDISE STORE: https://wrestle-addict-radio-shop.fourthwall.com/collections/kings-of-the-rings-podcast TWITTER (X): https://twitter.com/KOTR_PodcastINSTAGRAM: https://www.instagram.com/kotr_podcast/FACEBOOK: https://www.facebook.com/KOTRPodcast/DISCORD: https://discord.gg/5ggSgjGeaR FOLLOW WRESTLE ADDICT RADIO: https://linktr.ee/wrestleaddictradioOFFICIAL WAR MERCHANDISE: https://wrestle-addict-radio-shop.fourthwall.com Beats by AO Baker of The Signature Move Show (00:00) Intro(05:35) TNA Updates(18:50) AEW Updates(24:25) WWE/NXT Updates(39:20) WWE 2K26(47:15) Royal Rumble Saudi Preview(48:20) Men's Royal Rumble(01:03:20) Women's Royal Rumble(01:19:50) Gunther vs AJ Styles(01:30:15) Drew McIntyre vs Sami Zayn(01:37:20) Crown It(01:44:20) Outro

It's our very first show of the year AND one of our biggestshows of the year. It's our annual Royal Rumble preview show! ALL OUR LINKS: https://linktr.ee/KOTR_PodcastMERCHANDISE STORE: https://wrestle-addict-radio-shop.fourthwall.com/collections/kings-of-the-rings-podcast TWITTER (X): https://twitter.com/KOTR_PodcastINSTAGRAM: https://www.instagram.com/kotr_podcast/FACEBOOK: https://www.facebook.com/KOTRPodcast/DISCORD: https://discord.gg/5ggSgjGeaR FOLLOW WRESTLE ADDICT RADIO: https://linktr.ee/wrestleaddictradioOFFICIAL WAR MERCHANDISE: https://wrestle-addict-radio-shop.fourthwall.com Beats by AO Baker of The Signature Move Show (00:00) Intro(05:35) TNA Updates(18:50) AEW Updates(24:25) WWE/NXT Updates(39:20) WWE 2K26(47:15) Royal Rumble Saudi Preview(48:20) Men's Royal Rumble(01:03:20) Women's Royal Rumble(01:19:50) Gunther vs AJ Styles(01:30:15) Drew McIntyre vs Sami Zayn(01:37:20) Crown It(01:44:20) Outro

It's our very first show of the year AND one of our biggestshows of the year. It's our annual Royal Rumble preview show! ALL OUR LINKS: ⁠https://linktr.ee/KOTR_Podcast⁠MERCHANDISE STORE: ⁠https://wrestle-addict-radio-shop.fourthwall.com/collections/kings-of-the-rings-podcast⁠ TWITTER (X): ⁠https://twitter.com/KOTR_Podcast⁠INSTAGRAM: ⁠https://www.instagram.com/kotr_podcast/⁠FACEBOOK: ⁠https://www.facebook.com/KOTRPodcast/⁠DISCORD: ⁠https://discord.gg/5ggSgjGeaR⁠ FOLLOW WRESTLE ADDICT RADIO: ⁠https://linktr.ee/wrestleaddictradio⁠OFFICIAL WAR MERCHANDISE: ⁠https://wrestle-addict-radio-shop.fourthwall.com⁠ Beats by AO Baker of The Signature Move Show (00:00) Intro(05:35) TNA Updates(18:50) AEW Updates(24:25) WWE/NXT Updates(39:20) WWE 2K26(47:15) Royal Rumble Saudi Preview(48:20) Men's Royal Rumble(01:03:20) Women's Royal Rumble(01:19:50) Gunther vs AJ Styles(01:30:15) Drew McIntyre vs Sami Zayn(01:37:20) Crown It(01:44:20) Outro

You should download my free TOOLKIT for new record labels... http://otherrecordlabels.com/toolkit   Thanks to LANDR for sponsoring this episode. landr.com/otherrecordlabels   Contracts and royalties are where a lot of people get stuck—and for good reason. Record labels have a long history of bad deals, broken trust, and artists getting the short end of the stick. In Episode 7 of How to Start a Record Label This Year, Scott tackles this head-on and explains how modern independent labels can do things differently. This episode walks through the fundamentals of contracts and royalties from a practical, empathetic perspective—without legal jargon and without pretending there's a one-size-fits-all solution. In this episode, you'll learn: Why you do need contracts—and why they protect artists as much as labels When to involve a music attorney (and why templates and AI contracts fall short) Common contract terms artists actually care about (term length, exclusivity, territory) How licensing master recordings works for indie labels Why 50/50 profit sharing has become a modern standard How to structure fair splits while keeping the label sustainable The importance of having these conversations before any music is released Scott emphasizes that the most important part of any contract isn't the paperwork—it's the conversation. Clear expectations, honest communication, and transparency from day one are what turn contracts from something scary into something empowering.

In this raw, unfiltered conversation, Pimpin Ken, a former high-level pimp from Chicago and Milwaukee, breaks down the psychology, power dynamics, and realities of the pimping game during its peak in the 1970s–1990s. Ken speaks candidly about how he entered the life as a teenager, the culture of pimping that existed at the time, and how manipulation, control, and desensitization became central to survival. He explains the difference between street-level track work and higher-end strip club and VIP hustles, detailing how money was really made — and why most people misunderstand the game entirely. This interview also dives deep into: -The psychology behind control, power, and influence -How pimping was normalized in certain eras and communities -The role of trauma, abandonment, and emotional conditioning -Why he avoided violence and relied on manipulation instead -The evolution from street hustling to sophisticated financial setups -His thoughts on relationships, marriage, masculinity, and power -How prison, reading, and reflection changed his perspective This is not a glamorization — it's a firsthand account of a brutal system, told by someone who lived it and survived it. Support Ken Books: https://www.lulu.com/spotlight/PimpinKen7?srsltid=AfmBOoocrftoIFbUynb_2YpRlVnI7TyfLbkZk6L55Hq6d821w17fi1K5 Audio Book: https://www.audible.com/pd/Pimpology-Audiobook/B0196WKYU8?source_code=ASSGB149080119000H&share_location=pdp Hip Hop Fraternity: https://www.pimpinken.net/ This Episode Is #Sponsored By The Following: The Wellness Company! Power up with RECHARGE! Click https://twc.health/connect and use code CONNECT for 10% Off + Free Shipping on every order

On this episode of 83 Weeks, Eric Bischoff and Conrad Thompson take a deep dive into WWE's so-called royalty system. Eric weighs in on a recent social media post from Marc Mero that reignited the debate, offering his candid take on how things really work behind the scenes. The guys also break down the fallout from TNA's debut on AMC, including the disappointing ratings and reports of interest from a major hip-hop artist looking to buy the company. Plus, has WWE Unreal officially gone off the rails? Eric and Conrad share their unfiltered thoughts on Season Two of the Netflix series. It's a news-heavy, opinionated edition of 83 Weeks you won't want to miss. HARRY'S PLUS - Get the Harry's Plus Trial Set for only $10 at https://harrys.com/83WEEKS #Harryspod MARS MEN - Get 50% off FOR LIFE, Free Shipping AND 3 Free Gifts at Mars Men at http://Mengotomars.com  CHIME - Chime is not just smarter banking, it is the most rewarding way to bank. Join the millions who are already banking fee free today. It just takes a few minutes to sign up. Head to http://Chime.com/83WEEKS  . SIGNOS - Visit http://SIGNOS.com  and get 25% off select plans with code 83WEEKS.  STEVEN SINGER JEWELERS - No one does real diamond jewelry better. Experience the difference at Steven Singer Jewelers. Go online to http://IHateStevenSinger.com  today! Always fast and FREE shipping is waiting for you. BLUECHEW - Get 10% off your first month of BlueChew Gold with code 83WEEKS at http://BlueChew.com  PRIZE PICKS - Visit https://prizepicks.onelink.me/LME0/83WEEKS  and use code 83WEEKS to get $50 in lineups after you pay your first $5 lineup! SAVE WITH CONRAD - Stop throwing money away by paying those high interest rates on your credit card. Roll them into one low monthly payment and on top of that, skip your next two house payments. Go to https://www.savewithconrad.com  to learn more.

Find us at www.crisisinvesting.com   In this enlightening episode, Matt and Doug discuss the historic highs in silver, breaching $100 per ounce, and gold approaching $5000. They analyze the rapid movement in the precious metals markets, discuss strategies for holding and buying more, and delve into the lagging performance of mining stocks. They touch on broader economic issues, including Trump's political maneuvers, global unrest, and the absurdity of the ongoing drug war. Doug shares insights on historical U.S. territorial expansion, the implications of Alberta's potential secession, Trump's so-called 'Board of Peace,' and the intense dynamics involving China and other global powers. Listener questions spark discussions on diverse investing strategies, private ownership, and managing personal wealth amidst chaotic global markets. 00:00 Market Madness: Silver and Gold Surge 02:00 Mining Stocks: The Hidden Gems 04:17 Experts Roundtable: Insights and Discussions 06:43 Trump's WEF Speech and Political Reactions 08:16 The Board of Peace: Trump's Global Strategy 13:56 Drug War and Societal Issues 18:15 Global Territories: Greenland, Cuba, and More 30:21 The Pathological Behavior of Leaders 30:41 Jared Kushner's Vision for Gaza 31:40 The Unpredictable Future 32:53 Comparing Trump and Gorbachev 35:58 David Rogers Webb's Choice to Stay in Europe 41:52 Investing in Newsletters and Media Outlets 51:27 Alternative Investments: Farmland and Royalties 56:10 The Future of the US Dollar 58:49 Conclusion and Farewell

Flea revealed that his new solo album ‘Honora' will be coming out on March 27th and also announced a small accompanying NA and UK tour to support it,  Bandcamp has become one of the first major music streaming platforms to ban music that is fully generated or relies heavily on AI, Sting has paid $800k in unpaid royalties so far to his Police bandmates since their legal battle in court kicked off in late 2024, ex-Sex Pistols singer John Lydon admits he appeared on the recent season of The Masked Singer UK so he could get the money to record a new PIL album, A new documentary about Paul McCartney's band Wings will debut on Amazon Prime Video on February 27… PLUS ‘This Week in Rock & Roll History Trivia', Rock Birthdays, ‘The Best & Worst Rock Album Artwork of the Week' & much more!All of our links are up at www.rocknewsweekly.com every Monday, where you can check out the full episode on 8 different platforms (including Amazon Audible & Apple/Google Podcasts)Watch us LIVE, chat with us & more…Every Sunday around 2pm PST @ https://www.twitch.tv/rocknewsweeklyWatch all of our videos, interviews & subscribe at Youtube.com/@rocknewsweeklyFollow us online:Instagram.com/rocknewsweeklyFacebook.com/rocknewsweeklyTwitter.com/rocknewsweeklyTikTok.com/@rocknewsweekly#Flea #Sting #Bandcamp #JohnLydon #ManOnTheRun#Rock #News #RockNews #RockNewsWeekly #RockNewsWeeklyPodcast #Podcast #Podcasts #Metal #HeavyMetal #Alt #Alternative #ClassicRock #70s #80s #90s #Indie #Trivia #RockTrivia #RockBirthdays #NewMusic #NewMusicReleases

An independent musician seeks advice on skipping out on Spotify. Royalties for most artists are dismal on streaming services—is corporate licensing for background music a better option? Side Hustle School features a new episode EVERY DAY, featuring detailed case studies of people who earn extra money without quitting their job. This year, the show includes free guided lessons and listener Q&A several days each week. Show notes: SideHustleSchool.com Email: team@sidehustleschool.com Be on the show: SideHustleSchool.com/questions Connect on Instagram: @193countries Visit Chris's main site: ChrisGuillebeau.com Read A Year of Mental Health: yearofmentalhealth.com If you're enjoying the show, please pass it along! It's free and has been published every single day since January 1, 2017. We're also very grateful for your five-star ratings—it shows that people are listening and looking forward to new episodes.

In this episode of Mining Stock Education, host Brian Leni interviews Brian Dalton, CEO of Altius Minerals, to discuss the current state of the mining royalty sector. They delve into various topics including the competitive edge among royalty companies, contrarian opportunities in the market, and Altius's recent acquisition of Lithium Royalty Corp. Dalton shares his perspective on the importance of royalty and streaming financing, the impact of new entrants like Tether in the market, and how geopolitical factors and deglobalization are shaping the sector. He also discusses the challenges and opportunities in asset selection, the implications of market overshoots, and the future of the mining industry. Listeners will gain valuable insights on how to think like a CEO of a royalty company and make informed investment decisions. 00:00 Introduction 00:30 Current State of the Mining Royalty Sector 01:12 Consolidation and New Entrants in the Royalty Space 01:39 The Role of Royalties in Mining Financing 04:27 Tether's Entry into the Royalty Space 07:42 Investor Perspectives and Market Dynamics 22:08 Contrarian Opportunities in the Mining Sector 28:08 The Commitment of a Royalty Investor 28:53 Investor vs. Businessman: Key Differences 29:28 The Importance of Market Valuation 30:13 Navigating Emotions in Investment 30:52 Discussing the Lithium Royalty Corp Acquisition 31:46 Lithium Market Dynamics and Growth 40:16 The Role of Geopolitics in Resource Investment 44:17 Balancing Cash and Shares in Deals 46:34 Ranking Opportunities in the Metals Market 51:24 Altius's Market Presence and Future Plans Altius Minerals: https://altiusminerals.com/ Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 This interview was NOT sponsored. Mining Stock Education offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

What does it really mean to own a song? In this episode of Duologue, Leslie sits down with Josh Gruss, founder and CEO of Round Hill Music, to explore the hidden business behind the songs we love. From Nashville songwriting rooms to global music catalogs, Josh breaks down how songs are created, who owns them, and how royalties actually work. They discuss the difference between songwriters and artists, why publishing rights matter, and how iconic songs can generate value for decades. The conversation also unpacks high-profile ownership disputes, including Taylor Swift's rerecordings, and explains why music publishing is often described as the “real estate” of the music industry. Along the way, Josh shares his unconventional career path from finance to founding one of the world's leading music publishing companies — and why great songs tend to stand the test of time.Hosted on Ausha. See ausha.co/privacy-policy for more information.

In this episode I'm pulling back the curtain on the biggest moves I've made in order to maximize my royalties. I'll walk you through how my international royalties started flowing faster and more predictably, how I simultaneously quadrupled my BMI royalties, and why consistency became the real secret to my success. If you're trying to build sustainable sync licensing income and wondering what actually works, I'm sharing exactly what I did, the mistakes I made along the way, and the strategies that finally got me on track toward full-time royalty income.   want a free coaching call with me? https://www.roymatz.com/coaching   Michael Maas Courses:  Sync Music Business Course https://roymatz.krtra.com/t/7R1Cl8hft4oQ   Trailer Music Production https://roymatz.krtra.com/t/uYdZ26NTCfa4

Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article "Association Between Systemic Anticancer Therapy Administration Near the End of Life with Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality," highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at EOL (end of life) and the need for better communication between oncologists and patients regarding expected risk and benefits of such treatments to properly align goals-of-care. TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. Maureen Canavan, epidemiologist and associate research scientist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; and by Dr. Kerin Adelson, Chief Quality and Value Officer, medical oncologist, and clinical researcher on health services and clinical care delivery at MD Anderson Cancer Center. In the manuscript "Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER-Medicare Analysis of End-of-Life Care Quality." that you recently published in the JCO, you performed an analysis that included more than 30,000 older adults in the SEER-Medicare database, and you observed that 7.6% of these patients received any systemic anticancer medication within 30 days of death. So, I wanted you to explain why you thought that this was a priority right now, and whether there was any previous data that was published in the literature, and if you think that there was any significant gap in the literature that led you to the research you just published. Dr. Kerin Adelson: We have published a series of articles looking at real-world trends  in patterns of care, particularly related to systemic anticancer therapy at the end of life. This has been gaining increasing focus in recent years because of the understanding that when patients stay on systemic anticancer therapy, that is often a surrogate for a lack of goal-concordant care. So, patients who continue to receive systemic therapy have worse quality of life, are more likely generally to have a medicalized death, and less likely to use hospice. And what our prior work has shown is that more and more we are seeing patients using immunotherapies and targeted therapies towards the end of life. No prior work had really comprehensively examined whether these novel therapies were associated with those same patterns of care increases in acute care utilization and decreases in hospice. Dr. Davide Soldato: So basically, the data that we had up until that point was mostly with cytotoxic chemotherapy, and the emergence of this new treatment, which frequently are thought to be less toxic and so less problematic also in the end of life, led to this research. Is that correct? Dr. Kerin Adelson: Correct. Dr. Maureen Canavan: I would also build on that. I think that as the landscape of cancer care changes, it is important to really understand the availability of treatments, but then also, as Kerin noted, it is important to focus on goal-concordant care. We have established literature, studies we have done and some other studies that have looked at cytotoxic chemotherapy, but with the emergence of these targeted therapies, we really did not know a few things. We did not know the rates of utilization in a large national population, and how that was associated with these elements of medicalized death like ED use, hospitalizations, acute care use. So this was really a question that we had going into it. How can we expand the knowledge base so that both patients and providers can be more cognizant when thinking about goals of care conversations and ensuring that that is in place? Dr. Kerin Adelson: And our work has kind of evolved to answer some critical questions. So, one of our early papers looked at different rates of systemic anticancer therapy at the end of life, and that is where we showed that we were seeing a lot more immunotherapy and targeted therapy. And then we asked the question, well, oncologists generally when they give these treatments, they are hoping that those treatments are going to work and help the patients live longer. So we did another paper where we actually looked at practices who were more aggressive near the end of life and whether they had better overall survival than practices that were less aggressive, accounting for the fact that there could be populations of patients who benefited. And in fact, we showed there was no survival difference. So then this paper sort of answered the question: Well, if it is not having benefit, is this treatment actually doing harm? And this study gets at that question: What are the harms of continuing patients on therapy past the point of benefit? Dr. Maureen Canavan: And I think building off of that, the use of the SEER-Medicare database is a quite robust database. So in this, we have very specific data we can track. We can track the exact type of treatment they had, you know, was it a targeted therapy? Was it immunotherapy? So looking at those subclasses of therapy. We were also able to directly link it within that time frame to the acute care utilization, a limitation that we had in some of our previous work that that data was not always available. So it is more focused in the sense that we were looking at older adults, so patients 66 years of age and older, but we were able to get those individual metrics. So to Kerin's point, we did not see the survival benefit. What do we see then for these medicalized death elements? So the higher rates of all of them across the board. Dr. Davide Soldato: So coming back to the cohort and to the data that you utilized, Dr. Canavan mentioned the use of the SEER system to analyze these data. You already mentioned that you included mostly older adults, so those aged 66 and more. And also there was a little bit of restriction regarding the fact that the patient needed to be covered by Medicare in the last year of death concerning Part A and Part B, and the last 30 days from death concerning Part D. So I just wanted to ask a little bit of a question regarding these findings and whether you think that we also need additional work, especially in the younger population because I think it is something that all of us who work in oncology have seen. The aggressiveness, and this is also something that you showed in your data, tends to increase as the age of the patient tends to decrease. So we tend to be more aggressive towards younger patients. So just a comment on that on the population and generalizability of the findings. Dr. Maureen Canavan: Yeah, I will start with the data question element. Thank you. I think there are a few things to point out for that. So in terms of the restriction to ensure that they had continuous Part D coverage, that was necessary for us to track their oral medication use during that time. So kind of an easy response. The Part A, Part B requirement, it is actually pretty widely used in studies of SEER-Medicare data, and that is you want to establish the patient population, that they are not getting treated with another insurance provider in some way that you are not able to track. So that ensures that we can track not only their systemic anticancer therapy use but also when we are trying to make sure that we are controlling for confounders like chronic conditions and stuff, we are able to track the presence of chronic conditions. So we wanted to make sure we were not biasing the data, so I think that was an important consideration. You do point out very wisely that there are then limitations with the generalizability, and I think we would be lacking if we did not account for that. But I think it is important to establish this baseline relationship association, and then you can step out, we will say, to more diverse populations. So I think we could potentially maybe try to relax the timeline to see if people that might have influx in and out of the Medicare system are still seeing those same rates. I think it is likely they would. But I think to the bigger point that you bring up is that establishing this within the older adults where, you know, we do see as they get older maybe less rates of systemic therapy, extending it to the younger population. There is a challenge with that in that just that data is not available to the robust level that SEER-Medicare is. Both Kerin and I have noted that there is the possibility to look within one specific insurance provider type. Again, recognizing the limitations of the generalizability, but always slowly pushing the needle, finding out more about younger adult populations. And I think this is maybe in an ideal world, but setting the precedent that we really do need to track this on a national scale within younger adults because they do have the need. We do see these higher rates of utilization, and really making sure again with the mindset always of the best interest of patients and the most informative to providers in how we are looking at care. So I think generalizability is definitely a goal. However, there are limitations of the availability of data for younger populations and I think that they are a necessary restraint that all researchers should acknowledge. Dr. Kerin Adelson: Yeah, I think it is important for our audience to understand that health services research and large database research is really limited by what databases are available and what are the characteristics of those databases. So we have done a lot of work in an electronic health record database, and there you can get certain kinds of granularity that you may not be able to get in a payer or a claims-based database. But what you do not get is that comprehensive look at, say, what happens if a patient goes to another practice. Claims-based databases offer you that, but research on US populations is limited by our payment system. So when you look at younger patients, there are so many different insurance companies that when you are trying to get that comprehensive view, it can be hard or very expensive actually. These commercial insurers will sell their data to different databases. So for us, the largest single payer in the United States is the US government, and that is for patients who are over age 65, and that is why you see lots of US-based studies done in the Medicare population. Interestingly, a recent paper by a Canadian group showed very, very similar patterns. It was a significantly smaller study but, right, Canada is a single-payer system and so they were able to really look at all ages, and we did see the same patterns of care in a different payment system. Dr. Davide Soldato: Going back a little bit to the type of treatments that were observed in your manuscript, so we start from a 7.6% of patients who received any type of systemic anticancer therapy within 30 days from death. And when we split the different categories that you analyzed, which I think is a very strong aspect of your manuscript, we see that more or less 50% of the patients received chemotherapy, 20% more or less received immunotherapy, more or less 20% targeted therapy, and then there is a combination of those agents. So just wanted to have a little bit of your opinion compared also to the data that you already published and that you mentioned before. Was this in line with previous data? Was there anything surprising about this? We saw a little bit of a raise in the use of immunotherapy and targeted therapy as you were saying, but still, there is a very high proportion of chemotherapy, 50%. Dr. Kerin Adelson: So I think that really, really reflects the time period in which we studied where immunotherapies were gaining ground. There was tons of excitement and we were seeing this shift. I bet if we do the same study in five years that chemotherapy percent may even go down to half, and we are going to see more and more targeted and immunotherapies, and that is just reflecting the pattern of drug discovery that we are seeing. Dr. Davide Soldato: Coming to the real question that you wanted to answer with this manuscript, so is systemic anticancer therapy associated with worse outcomes in terms of healthcare utilization and use of hospice resources? Was there any hint that for example immunotherapy was related to less of these adverse outcomes? Dr. Kerin Adelson: So I will be honest, I was a little bit surprised that the combination of chemotherapy and immunotherapy was that much more strongly correlated with acute care use at the end of life. You know, I had really thought most likely that what we would see were similar rates. And we did. Each different type of systemic anticancer therapy was associated with significantly higher odds of ending up in the hospital, going to the ICU, dying in the hospital, going to the ED. But that group that got dual therapy was that much higher, you know, over three times the risk. And that surprised me because what it suggested is that there is likely a component of treatment toxicity that is leading to some of the acute care use. It is not simply just a constellation of patients who have not yet transitioned towards hospice or palliative care or end-of-life care who are then more likely to end up in the hospital. But the fact that we see a difference between, say, single-agent immunotherapy and dual combination with chemotherapy does suggest that the treatments are actually contributing to some of what we are seeing. Dr. Davide Soldato: But still, all of the treatments that you evaluated were still associated with higher healthcare utilization. Like there was no signal that, for example, giving immunotherapy at the end of life was not associated with these adverse outcomes. Correct? Dr. Kerin Adelson: Correct. And you will find oncologists out there who will say, actually, these treatments are so good that they might actually lower rates of hospitalization because they keep patients healthy. And certainly, that may be true upstream or earlier in the course of disease, but at the end of life, any form of systemic anticancer therapy is really a surrogate marker for lack of transition towards what is likely appropriate end-of-life therapy. And I just want to point out that time spent in the hospital, going back and forth to invasive procedures, going to the intensive care unit, even going back and forth to an infusion center, that is time that is not spent at home with loved ones for people who have very little time left to live. Dr. Davide Soldato: Thank you very much. That was exactly the point that I wanted you to stress because I think it is really the most important message that we can get as oncologists from this manuscript. Like there is no treatment that is not associated with potentially harming our patient and, as you were saying, taking off time with loved ones in a critical period of the life of these individuals who have been diagnosed and treated for cancer. So, basically what we saw in the paper was a 7.65% utilization of systemic anticancer therapy. And I might imagine that for some oncologists or for some hematologists that might not actually be that much. Like they could potentially say, "Okay, but it is like 7%, it is not that high. I would have expected something higher." So I just wanted a little bit of perspective regarding also quality metrics that we have available for these types of indicators at end-of-life care. What would be the appropriate percentage of people receiving any type of treatment within 30 days from death? Dr. Maureen Canavan: A couple caveats, as a data person I always like to give those. This was among all cancer patients, so not necessarily patients that had been on active treatment. So I think that number was actually quite lower than when we looked in another study about patients that had chemo within the last year, so on, you know, active treatment. So I think that is an element to take into consideration is that those numbers will vary based on who your denominator population is. So that is important to consider. Additionally, the National Quality Forum, they call for reducing rates of systemic therapy at end of life. But I think they, similar to how I would be, are cautious to point out this is the exact number, or it should be zero. Because there are cases where you have to go in line with patient preferences. And if a patient is very adamant that they want to continue treatment, that needs to be a decision that comes between them and their provider. So, you know, the zero, though sounding ideal to us who want to encourage transitions and encourage goals of care conversation is a nice number, it is not a realistic. So, to evade your question completely, I do not think there is a set number. But the goal is to make sure that both patients, providers, everyone is informed and is making the best holistic decision. So there is this natural tendency, I think, to keep fighting both for the patient and the provider to try to beat something, but recognizing the point at which we are beyond a benefit of treatment and what would be most beneficial to the patient in terms of getting back to that idea of, you know, the time with their families and whatnot. So is the number zero? No. Could it probably be lower than we have? I think yes, definitely. Dr. Kerin Adelson: I completely agree with everything Dr. Canavan said. I think one of the other challenges is that this data isn't being tracked and publicly reported across the world. And so what that optimal rate is, is a little unclear. We see different rates also depending on the population included. So one of the things Dr. Canavan said is our database included patients who were likely treated long ago for cancer and cured of their cancer. So they were less likely to die on systemic therapy. But until everybody starts tracking and reporting, it is really hard to know where we are as a country or really as a global population, and then what are the bars that we want to achieve in driving down the rates. I think some data shows that probably something in the range of 10% or below, you know, for patients who have more active cancer is probably where we should be going and driving towards. But until we have more public reporting of these metrics and consistency in how we measure them, it is really hard to come up with a single number. Dr. Davide Soldato: I have the impression that sometimes there is also a little bit of difficulty for the oncologist or the hematologist to really understand who are the patients who are approaching end of life. So there has been some data and you also report some of them in the discussion of the manuscript regarding, for example, prompts inside of the electronic health records or the use of artificial intelligence to try to predict what is the disease course. So just wanted a little bit of perspective if you think that these tools could potentially be helpful and if you think that we will be able at a certain point to implement them in routine clinical care. Dr. Kerin Adelson: I have been working on trying to do this actually at MD Anderson and coming up with a really reliable data tool that will tell us who are the patients who are going to die in short order after receiving systemic anticancer therapy. And it is not that easy, I will say. So, you know, I think we all want this amazing machine learning model that is incredibly reliable. But like any statistical test, there are problems, right? So a very sensitive test that is going to identify high, high risk of dying at the end of life is going to be compromised by false positives. And when an oncologist knows that the test might be a false positive, it becomes very hard for them to take action on it. Similarly, you know, a very, very specific test is going to be compromised by false negatives. So in that case, you could end up having patients who are at risk for dying and still treating them with chemotherapy. And so, you know, I think in the end we need some tools. It will be great if machine learning becomes very reliable and we have the right structured data elements in our electronic health records to give these reliable prediction tools. But I think there are some basic things that we all know, and those are the markers of chronicity of cancer. So patients who have had multiple lines of therapy already, right? Past the point of clinical trial benefit. Patients who have lost significant amounts of weight. Patients who are not getting out of bed and have worse performance status. Patients who are increasingly confused, right? And not mentally engaging the way they did previously. Those markers have been shown in numerous publications by a colleague of mine, David Hui and others, to really be pretty strong predictors, and they resonate with clinicians more than a machine learning score might. You know, I think when clinicians do not understand what the elements in a machine learning tool are, they are less likely to trust it and more likely to say, "Oh, it is a false positive or a false negative." But very few clinicians can argue against the fact that the patient who hasn't gotten out of bed in two weeks is somebody who is less likely to benefit. Dr. Davide Soldato: Dr. Adelson, I would like to close this podcast and I would like to thank you again for joining us today. Dr. Maureen Canavan: Thank you so much. Dr. Kerin Adelson: Thank you so much for having us. Dr. Davide Soldato: Dr. Canavan, Dr. Adelson, we appreciate you sharing more on your JCO article titled "Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER-Medicare Analysis of End-of-Life Care Quality." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can f ind all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Disclosures Kerin AdelsonStock and Other Ownership Interests: Carrum Health Consulting or Advisory Role: Abbvie, Quantum Health, Gilead SciencesPatents, Royalties, Other Intellectual Property: Genentech Other Relationship: Genentech/Roche Employment: Emilio Health/Brightline Health(An Immediate Family Member) Stock and Other Ownership Interests: Emilio Health/Brightline Health, Lyra Health (An Immediate Family Member)

“We were a very valuable deep-science company that had the wrong business strategy,” Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company’s strategic reset, Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances innovation with capital discipline. The conversation covers zanidatamab’s path to market, lessons from partnering with Jazz and BeOne, the value of asymmetric antibody design and why retaining upside through milestones and royalties could reshape long-term value creation.See omnystudio.com/listener for privacy information.

12-20-25 - Entertainment Drill - MIX - John Hinkley Owed Royalties From A Devo Song - Lil Nas X Song On Next Kidz Bop Album - 2021 - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

12-20-25 - Entertainment Drill - MIX - John Hinkley Owed Royalties From A Devo Song - Lil Nas X Song On Next Kidz Bop Album - 2021 - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Grab our breakdown of the 5 Low-Cost Businesses That Make $1 Million: https://www.franchiseempire.com/lowcost?utm_source=TJJan032025If you liked this video, but want to learn about franchises with higher profit margins check out this video next: https://youtu.be/voDIBiM58awThinking about investing in a Culver's franchise? In this breakdown, I cover startup costs, royalty fees, average sales, and why it might not be as profitable as it looks. We'll also talk about scalability, margins, and whether it's a smart move going into 2026. You'll also learn more about the brand's history and how it has grown so quickly in some parts of the US. Make sure you watch before you invest!------------------Considering Investing In A Franchise?

Make sure you don't miss out on my Most Incredible Franchise Gift Ever: https://www.franchiseempire.com/mifge?utm_source=TJdec132025If you liked this video, but want to find out about franchises with lower start up costs, check out this video: https://youtu.be/voDIBiM58awArby's is one of the most recognizable fast food franchises, but is it actually a good investment? In this video, we break down the full numbers behind owning an Arby's in 2025, including startup costs, royalty fees, average unit sales, and top vs. bottom-performing locations. You'll learn how much franchisees are really making, how Inspire Brands plays a role, and whether the economics make sense for today's buyer. If you're researching fast food or sandwich franchises, this video will give you the clarity you need before making a move.------------------Considering Investing In A Franchise?

Artist Sara Pichelli discussed the royalties she gets from Miles Morales, or lack thereof. The Beauty is getting a new printing in advance of the Hulu TV series. Lake Como Comic Art Festival announces guest list.SUBSCRIBE ON RSS, APPLE, SPOTIFY, OR THE APP OF YOUR CHOICE. FOLLOW US ON BLUESKY, INSTAGRAM, TIKTOK, AND FACEBOOK. SUPPORT OUR SHOWS ON PATREON.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

D J Newmark Take a walk with me down Fascination Street as I get to know 'The Legendary Throwback King' himself, D J Newmark. In this episode, we chat about his growing up as a military dependent and traveling the world learning about how different countries and cultures make their mark on Hip Hop. Then we dive into how and why he decided to pursue a career as a DJ. He has toured with some of the biggest names in the genre, and he shares a couple of those road stories. Then we talk about his radio show. Catch the "Legendary Throwback King" on the airwaves weekdays from 3-7 pm EST as the host of "The DJ NEWMARK EXPERIENCE" radio show on YO! 107.1 FM (WLLY-HD3), West Palm Beach, Florida's premiere radio station for classic Hip-Hop and R&B music. They also simulcast live on the web @ www.yopalmbeach.com.  DJ Newmark also hosts a mix show segment called "The Flavor on Top of Flavor Master Mix" weekdays at 5:30pm EST. We also delve into Newmark's experience coaching youth basketball, and some of the other ways he gives back to his community. Lastly, we discuss his new line of Throwback inspired street wear. I have one of the shirts in his line, and it is so soft and comfortable that I can't stop wearing it. Check out the Throwback inspired line and everything else about D J Newmark on his website: DJNewmark.com

Self-published authors Anne Ditmeyer and Martin Lake share what it really takes to go indie, from choosing platforms and budgeting for editing, design, and ISBNs to redefining success, avoiding scams, and playing the long game of finding readers and building a sustainable writing life.  You'll learn:Why Anne and Martin chose self-publishing over traditional routes and how they framed readers as their gatekeepers.How both authors define success beyond bestseller lists, from “book as business card” to improving the craft across 25 books.The real timelines of an indie career, including slow early sales, backlist effects, and why self-publishing is a marathon, not a sprint.What a realistic budget looks like for editing, design, typesetting, audiobooks, and print on demand, plus where they chose to DIY or outsource.How they use platforms such as Kindle Direct Publishing, Lulu, IngramSpark, Draft2Digital, and Shopify, and why most sales still come through Amazon.Practical approaches to marketing that do not require a huge following, including series, mailing lists, events, workshops, and using your existing communities.The role of ISBNs, imprints, metadata, and print on demand for getting into libraries and bookstores, and why in-store placement is harder than it looks.Red flags to watch for with third-party “publishing services” and why due diligence can save you thousands in fees and frustration.   Resources and Links:

It's karaoke night for Bridget and Ryan, but something stops them from belting their favorite tunes on their podcast: the law. It's the perfect setup to answer a question from Garrett, who wants to know about copyright, trademarks, and royalties. We all know people deserve to be paid for their creative ideas. But how does it actually work? Together, we'll find out how creators protect their ideas and make money from them. Plus, will Ryan be able to turn what he's learned into a lucrative musical career?If your family is interested in learning even more about today's question, check out our website. We've got conversation starters and a tip sheet!This episode is sponsored by Greenlight. Sign up for Greenlight today at greenlight.com/million.

It's karaoke night for Bridget and Ryan, but something stops them from belting their favorite tunes on their podcast: the law. It's the perfect setup to answer a question from Garrett, who wants to know about copyright, trademarks, and royalties. We all know people deserve to be paid for their creative ideas. But how does it actually work? Together, we'll find out how creators protect their ideas and make money from them. Plus, will Ryan be able to turn what he's learned into a lucrative musical career?If your family is interested in learning even more about today's question, check out our website. We've got conversation starters and a tip sheet!This episode is sponsored by Greenlight. Sign up for Greenlight today at greenlight.com/million.

Let's talk about Trump and Obamacare royalties....

Bryan Kohberger can't leave his cell — but his story can. In the state of Idaho, there's no Son of Sam law, meaning that a convicted murderer can legally make money from the story of his crimes. Books. Documentaries. Interviews. Royalties. In this episode, Tony Brueski and former prosecutor Eric Faddis expose how one of the most horrifying modern murder cases has collided with one of America's oldest constitutional blind spots: the First Amendment's protection of speech — even when that speech turns into profit from murder. Tony opens with the question every viewer needs to hear: How can a convicted killer make money from killing? The answer lies in a 1991 Supreme Court ruling, Simon & Schuster v. Crime Victims Board, which struck down New York's original Son of Sam law after the “Son of Sam” killer, David Berkowitz, tried to sell his story. The Court ruled that laws restricting “crime-based storytelling” discriminated against speech by content. States rewrote their laws to pass constitutional review — some succeeded, others failed — but Idaho never passed anything. The result: a legal vacuum where infamy becomes an industry. This episode breaks down the moral, legal, and economic consequences of that loophole. What does it mean for victims' families when killers can cash checks? Could Kohberger assign rights to a third party to hide profits? And why are lawmakers too afraid to fix it? Tony and Eric dissect how “freedom” became a shield for greed, how fear of being called unconstitutional paralyzed reform, and why the justice system now doubles as a business model. Justice shouldn't have a payout plan. This episode asks why America keeps writing one. #BryanKohberger #SonOfSam #TrueCrime #JusticeSystem #CrimePodcast #VictimsRights #TonyBrueski #EricFaddis #KohbergerTrial #FreeSpeech #MurderProfit #TrueCrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Bryan Kohberger can't leave his cell — but his story can. In the state of Idaho, there's no Son of Sam law, meaning that a convicted murderer can legally make money from the story of his crimes. Books. Documentaries. Interviews. Royalties. In this episode, Tony Brueski and former prosecutor Eric Faddis expose how one of the most horrifying modern murder cases has collided with one of America's oldest constitutional blind spots: the First Amendment's protection of speech — even when that speech turns into profit from murder. Tony opens with the question every viewer needs to hear: How can a convicted killer make money from killing? The answer lies in a 1991 Supreme Court ruling, Simon & Schuster v. Crime Victims Board, which struck down New York's original Son of Sam law after the “Son of Sam” killer, David Berkowitz, tried to sell his story. The Court ruled that laws restricting “crime-based storytelling” discriminated against speech by content. States rewrote their laws to pass constitutional review — some succeeded, others failed — but Idaho never passed anything. The result: a legal vacuum where infamy becomes an industry. This episode breaks down the moral, legal, and economic consequences of that loophole. What does it mean for victims' families when killers can cash checks? Could Kohberger assign rights to a third party to hide profits? And why are lawmakers too afraid to fix it? Tony and Eric dissect how “freedom” became a shield for greed, how fear of being called unconstitutional paralyzed reform, and why the justice system now doubles as a business model. Justice shouldn't have a payout plan. This episode asks why America keeps writing one. #BryanKohberger #SonOfSam #TrueCrime #JusticeSystem #CrimePodcast #VictimsRights #TonyBrueski #EricFaddis #KohbergerTrial #FreeSpeech #MurderProfit #TrueCrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Wyoming made billions from coal mining over the last 50 years, funding the government, schools, roads, parks. But President Trump's major spending bill, passed in July, gives mining companies a break on royalty fees — leaving state budgets lean. In this episode, easing coal fees comes at a price. Plus: Non-store retail spending saw double-digit year-over-year growth, small businesses suffer as they wait for tariff clarity, and stock investors basically ignore all the bad economic headlines.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.